2026年

May 20, 2026: Notice of Dividends from Retained Earnings
May 12, 2026: Consolidated Financial Results for the Fiscal Year Ended March 31, 2026 [Under Japanese GAAP]
May 12, 2026: Consolidated Financial Results for the Fiscal Year Ended March 31, 2026
May 12, 2026: Notice Regarding Difference Between Financial Forecast and Actual Results
May 12, 2026: Financial Results of Fiscal 2025
May 12, 2026: Notice Regarding the Formulation of the New Medium-Term Business Plan "Vision 110－Stage2－"
May 12, 2026: Announcement of Executive Personnel Changes
May 12, 2026: Notice regarding Partial Revision of Performance-Linked Stock Compensation Plan
May 7, 2026: Notice Regarding the Initiation of a Confirmatory Study for "KRP-DT123," a Digital Therapeutic for Tinnitus
April 24, 2026: Notice Regarding Execution of a Memorandum of Understanding (MOU) for the Transfer of Generic Drug Business
March 31, 2026: KYORIN Enters into License Agreement with BIODOL for Novel Neuropathic Pain Treatment
March 25, 2026: KYORIN Enter into Distribution and Promotion Agreement with Johnson & Johnson for SIRTURO
March 23, 2026: KYORIN and UBE Enter into License Agreement for Novel Drug Candidates
February 26, 2026: Notice Regarding the Introduction of a Mandate-Based Corporate Officer System and Changes in Corporate Officers
February 4, 2026: KYORIN Receives Regulatory Approval for influenza virus nucleic acid kit, GeneSoC FluAB Detection Kit
February 4, 2026: Consolidated Financial Results for the Nine Months Ended December 31, 2025 - Supplementary Information
February 4, 2026: Consolidated Financial Results for the Nine Months Ended December 31, 2025 [Japanese GAAP]
January 5, 2026: KYORIN and Lunatus Enter into Distribution Agreement for Lasvic Tablets in Nine Middle Eastern Countries